Show simple item record

p53 Protein and Proliferating Cell Nuclear Antigen (PCNA) Expression in Small Round Cell Tumors of Bone and Adjacent Soft Tissue

dc.contributor.authorDevaney, Kennethen_US
dc.contributor.authorAbbondanzo, Susanen_US
dc.contributor.authorShekitka, Krisen_US
dc.contributor.authorWolov, Roberten_US
dc.contributor.authorSweet, Donalden_US
dc.date.accessioned2010-04-13T18:56:53Z
dc.date.available2010-04-13T18:56:53Z
dc.date.issued1995en_US
dc.identifier.citationDevaney, Kenneth; Abbondanzo, Susan; Shekitka, Kris; Wolov, Robert; Sweet, Donald (1995). "p53 Protein and Proliferating Cell Nuclear Antigen (PCNA) Expression in Small Round Cell Tumors of Bone and Adjacent Soft Tissue." International Journal of Surgical Pathology 2(4): 259-267. <http://hdl.handle.net/2027.42/66891>en_US
dc.identifier.issn1066-8969en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/66891
dc.description.abstractSixty small cell tumors of bone and adjacent soft tissue were studied in an attempt to define the incidence of immunohistochemically detectable p53 protein and cor relate these findings with the results of proliferating cell nuclear antigen (PCNA) immunohistochemical staining and mitotic counts. All of the lesions had been for malin-fixed and paraffin-embedded; half were subjected to decalcification prior to processing. The study population included 12 Ewing's sarcomas of bone, 3 atypical Ewing's sarcomas of bone, 3 primitive neuroectodermal tumors of bone, 11 Askin tumors of the thoracopulmonary region, 11 small cell osteosarcomas of bone, 10 mesenchymal chondrosarcomas of bone, and 10 malignant lymphomas involving bone. The patients ranged in age at the time of presentation from 17 to 67 years. Overall, the incidence of p53 positivity was extremely low in these lesions, irre spective of tumor type. Positive nuclear staining with an antibody to p53 was found in none of the 12 Ewing's sarcomas, none of the 3 atypical Ewing's sarcomas, none of the 3 primitive neuroectodermal tumors of bone, 1 of the 11 Askin tumors of the thoracopulmonary region (1.5% of tumor cells positive), 1 of the 11 small cell osteosarcomas (2% of tumor cells positive), 1 of the 10 mesenchymal chondrosar comas of bone (7% of tumor cells positive), and 2 of the 10 malignant lymphomas involving bone (0.5% and 1% of tumor cells positive, respectively). The majority of tumors showed PCNA positivity within the tumor cells, although the incidence of PCNA positivity within the histologic types varied greatly; in general, the higher PCNA counts corresponded to higher mitotic counts within the individual lesions. The present study did not demonstrate any correlation between mutant p53 accu mulation detected by immunohistochemistry and tumor type, and so it is unlikely that p53 positivity will prove to be of great use in the differential diagnosis of these lesions. A correlation between p53 positivity and PCNA staining or mitotic activity was not apparent. Int J Surg Pathol 2(4):259-268, 1995en_US
dc.format.extent3108 bytes
dc.format.extent1185003 bytes
dc.format.mimetypetext/plain
dc.format.mimetypeapplication/pdf
dc.publisherSage Publicationsen_US
dc.subject.otherEwing's Sarcomaen_US
dc.subject.otherAskin Tumoren_US
dc.subject.otherNeuroectodermal Tumoren_US
dc.subject.otherMesenchymal Chondrosarcomaen_US
dc.subject.otherSmall Cell Osteosarcomaen_US
dc.subject.otherLymphomaen_US
dc.subject.otherP53en_US
dc.subject.otherPCNA.en_US
dc.titlep53 Protein and Proliferating Cell Nuclear Antigen (PCNA) Expression in Small Round Cell Tumors of Bone and Adjacent Soft Tissueen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPathologyen_US
dc.subject.hlbsecondlevelSurgery and Anesthesiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumthe Departments of Pathology and Orthopaedic Surgery, Brown University, Rhode Island Hospital, Providence, Rhode Island, Department of Pathology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherthe Division of Immunohistochemistry, Armed Forces Institute of Pathology, Washington, DCen_US
dc.contributor.affiliationotherthe Department of Orthopedic Pathology, Armed Forces Institute of Pathology, Washington, DC.en_US
dc.contributor.affiliationotherthe Division of Immunohistochemistry, Armed Forces Institute of Pathology, Washington, DCen_US
dc.contributor.affiliationotherthe Department of Orthopedic Pathology, Armed Forces Institute of Pathology, Washington, DC.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/66891/2/10.1177_106689699500200401.pdf
dc.identifier.doi10.1177/106689699500200401en_US
dc.identifier.sourceInternational Journal of Surgical Pathologyen_US
dc.identifier.citedreferenceFellinger EJ, Garin-Chesa P., Glasser DB, Huvos AG, Rettig WJ Comparison of cell surface antigen HBA71 (p30/32MIC2), neuron-specific enolase, and vimentin in the immunohistochemical analysis of Ewing's sarcoma of bone. Am J Surg Pathol 16:746-755, 1992en_US
dc.identifier.citedreferenceTaylor C., Patel K., Jones T., Kiely F, De Stalvo BL, Sheer D. Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on detection of t(11;22) using fluorescent in situ hybridization. Br J Cancer 67:128-133, 1993en_US
dc.identifier.citedreferenceDevaney K., Vinh TN, Sweet DE Small cell osteosarcoma of bone—An immunohistochemical study with differential diagnostic considerations. Hum Pathol 24:1211-1225, 1993en_US
dc.identifier.citedreferenceHsu SM, Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabelled antibody procedures. J Histochem Cytochem 29:577-580, 1981 1en_US
dc.identifier.citedreferenceSoini Y., Vähägangas K., Nuorva K., Kamel D., Lane DP, Pääkkö P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J Pathol 168:29-33, 1992en_US
dc.identifier.citedreferenceUeda Y., Dockhorn-Dworniczak B., Blasius S., Mellin W., Wuisman P., Böcker W., Roessner A. Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 119:172-178, 1993en_US
dc.identifier.citedreferenceWadayama B., Toguchida J., Yamaguchi T., Sasaki MS, Kotoura Y., Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 68:1134-1139, 1993en_US
dc.identifier.citedreferenceKawai A., Noguchi M., Beppu Y., Yokoyama R., Mukai K., Hirohashi S., Inoue H., Fukuma H. Nuclear immunoreaction of p53 protein in soft tissue sarcomas—A possible prognostic factor. Cancer 73:2499-2505, 1994en_US
dc.identifier.citedreferenceDei Tos AP, Doglioni C, Laurino L, Barbareschi M, Fletcher CDM. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathol 22:45-50, 1993en_US
dc.identifier.citedreferencePatterson H., Gill S., Fisher C., Law MG, Jayatilake H., Fletcher Cdm, Thomas M., Grimer R., Gusterson BA, Cooper CS Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 69:1052-1058, 1994en_US
dc.identifier.citedreferenceInohara S. Immunohistochemical localization of p53 protein in malignant hemangioendothelioma. Acta Derm Venereol (Stockh) 74:161-162, 1994en_US
dc.identifier.citedreferenceOshiro Y., Fukada T., Tsuneyoshi M. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis— a comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53. Am J Surg Pathol 18: 712-719, 1994en_US
dc.identifier.citedreferenceMayall FG, Goddard H., Gibbs AR The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos-associated mesotheliomas. Histopathol 22:383-386, 1993en_US
dc.identifier.citedreferenceBourhis J. Oncogenes and tumor suppressor genes in human cancers: Clinical implications. Br J Radiol 24 (Suppl):215-219, 1993en_US
dc.identifier.citedreferenceHall EJ Review article: The gene as theme in the paradigm of cancer. Br J Radiol 66:1-11, 1993en_US
dc.identifier.citedreferenceYandell DW, Thor AD p53 analysis in diagnostic pathology—Biologic implications and possible clinical applications. Diagn Molec Pathol 2:1-3, 1993en_US
dc.identifier.citedreferenceHollstein M., Sidransky D., Vogelstein B., Harris CC p53 mutations in human cancers. Science 253:49-53, 1991en_US
dc.identifier.citedreferenceLevine AJ, Momand J., Finlay CA The p53 tumour suppressor gene. Nature 351:453-456, 1991en_US
dc.identifier.citedreferenceMalkin D., Li FP, Strong LC, Fraumenz JF, Nelson CE, Kim DH, Kassel J., Gryka MA, Bischoff FZ, Tainsky MA, Friend SH Germ line p53 mutations in a familial syndrome of breast can-cer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990en_US
dc.identifier.citedreferenceMc Kenzie SJ Diagnostic utility of oncogenes and their products in human cancer. Biochem Biophys Acta 1072:193-214, 1991en_US
dc.identifier.citedreferenceSidransky D., Von Eschenbach A, Tsai YC, Jones P., Summerhayes I., Marshall F., Paul M., Green P., Hamilton SR, Frost P., Vogelstein B. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709, 1991en_US
dc.identifier.citedreferenceTamura G., Kihana T., Nomura K., Terada M., Sugimura T., Hirohashi S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res 51:3056-3058, 1991en_US
dc.identifier.citedreferenceChiba I., Takahashi T., Nau MM, D'Amico D., Curiel DT, Mitsudomi T., Buchhagen DL, Carbone D., Pinatadosi S., Koga H., Reissman PT, Slamon DJ, Holmes EC, Minna JD Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancers. Oncogene 5:1603-1610, 1990en_US
dc.identifier.citedreferenceProsser J., Thompson AM, Cranston G., Evans HJ Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5:1573-1579, 1990en_US
dc.identifier.citedreferencePaquette RL, Lee YY, Wilczynski SP, Karmakar A., Kizaki M., Miller CW, Kowffler HP Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer 72:1272-1280, 1993en_US
dc.identifier.citedreferenceJoypaul BV, Newman EL, Hopwood D., Grant A., Qureshi S., Lane DP, Cuschieri A. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: An immunohistochemical study. J Pathol 170:279-283, 1993en_US
dc.identifier.citedreferenceNiedobitek G., Agathanggelou A., Barber P., Smallman LA, Jones EL, Young LS p53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol 170:457-461, 1993en_US
dc.identifier.citedreferenceCasson AG, Mukhopadhyay T., Cleary KR, Ro JY, Levin B., Roth JA p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51:4495-4499, 1991en_US
dc.identifier.citedreferenceSoini Y., Kamel D., Nuorva K., Lane DP, Vähäkangas K., Pääkkö P. Low p53 protein expression in salivary gland tumours compared with lung carcinomas. Virch Arch A Pathol Anat 421:415-420, 1992en_US
dc.identifier.citedreferenceNg H-K., Lo K-W., Huang DP, Poon W-S. p53 in low-grade gliomas. Int J Surg Pathol 1:163-170, 1994en_US
dc.identifier.citedreferenceCesarman E., Inghirami G., Chadburn A., Knowles DM High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:485-856, 1993en_US
dc.identifier.citedreferenceMatsushima AY, Cesarman E., Chadburn A., Knowles DM Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 144:573-584, 1994en_US
dc.identifier.citedreferenceKennedy SM, Macgeogh C., Jaffe R., Spurr NK Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 25:438-442, 1994en_US
dc.identifier.citedreferenceKovar H., Auinger A., Jug G., Aryee D., Zoubek A., Salzerkuntschik M., Gadner H. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8:2683-2690, 1993en_US
dc.identifier.citedreferenceKomuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 53:5284-5288, 1993en_US
dc.identifier.citedreferenceMulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863-5867, 1990en_US
dc.identifier.citedreferenceBoman F., Peters J., Ragge N., Triche T. Infrequent mutations of the p53 gene in fibrous tumors of infancy and childhood. Diagn Molec Pathol 2:14-22, 1993en_US
dc.identifier.citedreferenceSilverberg SG Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumors of the uterus. Hum Pathol 7:451-454, 1976en_US
dc.identifier.citedreferenceScully RE Mitosis counting. I. Hum Pathol 7:481-482, 1976en_US
dc.identifier.citedreferenceKempson RL Mitosis counting. II. Hum Pathol 7:482-483, 1976en_US
dc.identifier.citedreferenceNorris HJ Mitosis counting. III. Hum Pathol 7:483-484, 1976en_US
dc.identifier.citedreferencevan Diest PJ, Baak Jpa, Matze-Cok P., Wisse-Brekelmans Ecm, Van Galen CM, Kurver Phj, Bellot SM, Fijnheer J, Van Gorp LHM, Kwee WS, Los J, Peterse JL, Ruitenberg HM, Schapers RFM, Schipper MEI, Somsen JG, Willig AWPM, Arzens A Th. Reproducibility of mitosis counting in 2,469 breast cancer specimens: Results from the multi-center morphometric mammary carcinoma project. Hum Pathol 23:603-607, 1992en_US
dc.identifier.citedreferenceSimpson JF, Dutt PL, Page DL Expression of mitoses per thousand cells and cell density in breast carcinomas: A proposal. Hum Pathol 23:608-611, 1992en_US
dc.identifier.citedreferenceBaak Jpa. Mitosis counting in tumors. Hum Pathol 21:683-685, 1990en_US
dc.identifier.citedreferenceEllis Psj, Whitehead R. Mitosis counting—A need for reappraisal. Hum Pathol 12:3-4, 1981en_US
dc.identifier.citedreferenceZuckman MH, Williams G., Levin HS Mitosis counting in seminoma: An exercise of questionable significance. Hum Pathol 19:329-335, 1988en_US
dc.identifier.citedreferenceOjanguren I., Ariza A., Llatjos M., Castella E., Mate JL, Navas-Palacios JJ Proliferating cell nuclear antigen expression in normal, regenerative, and neoplastic liver: A fine-needle aspiration cytology and biopsy study. Hum Pathol 24:905-908, 1993en_US
dc.identifier.citedreferenceFonseca I., Soares J. Proliferating cell nuclear antigen immunohistochemistry in epithelial-myoepithelial carcinoma of the salivary glands. Arch Pathol Lab Med 117:993-995, 1993en_US
dc.identifier.citedreferenceKitamoto M., Nakanishi T., Kira S., Kawaguchi M., Nakashio R., Suemori S., Kajiyama G., Asahara T., Dohi K. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 72: 1859-1865, 1993en_US
dc.identifier.citedreferenceNielsen AL, Nyholm Hcj. Proliferating cell nuclear antigen in endometrial adenocarcinomas of endometrioid type correlated with histologic grade, stage, previous hormonal treatment, and survival. Hum Pathol 24:1003-1007, 1993en_US
dc.identifier.citedreferenceDelahunt B., Bethwaite PB, Nacey JN, Ribas JL Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: Comparison with tumor grade, mitotic index, and silver-staining nucleolar organizer region numbers. J Pathol 170:471-477, 1993en_US
dc.identifier.citedreferenceHorny H-P., Schumacher U., Mc Cullagh P., Wehrmann M., Roche WR, Kaiserling E. Proliferation of reactive neoplastic human tissue mast cells: An immunohistochemical study using the antibody PC10 (anti-PCNA). J Pathol 170:265-270, 1993en_US
dc.identifier.citedreferenceOda Y., Hashimoto H., Takeshita S., Tsuneyoshi M. The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer 72:478-485, 1993en_US
dc.identifier.citedreferencePendleton N., Dixon GR, Burnett HE, Occleston NL, Myskow MW, Green JA Expression of proliferating cell nuclear antigen (PCNA) in dysplasia of the bronchial epithelium. J Pathol 170:169-172, 1993en_US
dc.identifier.citedreferenceRoos G., Landberg G., Huff JP, Houghten R., Takasaki Y., Tan EM Analysis of the epitopes of proliferating cell nuclear antigen recognized by monoclonal antibodies. Lab Invest 68:204-210, 1993en_US
dc.identifier.citedreferenceColtrera MD, Skelly M., Gown AM Anti-PCNA antibody PC 10 yields unreliable proliferation indexes in routinely processed, deparaffinized, formalin-fixed tissue. Appl Immunohistochem 1:193-200, 1993en_US
dc.identifier.citedreferenceMc Cormick D., Hall PA The complexities of proliferating cell nuclear antigen. Histopathol 21: 591-594, 1992en_US
dc.identifier.citedreferenceMc Cormick D., Yu C., Hobbs C., Hall PA The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathol 22:543-547, 1993en_US
dc.identifier.citedreferenceIsik FF, Ferguson M., Yamanaka E., Gordon D. Proliferating cell nuclear antigen—A marker for cell proliferation in autopsy tissues. Arch Pathol Lab Med 116:1142-1146, 1992en_US
dc.identifier.citedreferenceStart RD, Cross SS, Clelland C., Silcocks PB, Rogers K., Smith Jhf. Delay in fixation does not affect the immunoreactivity of proliferating cell nuclear antigen (PCNA). J Pathol 268:197-199, 1992en_US
dc.identifier.citedreferenceTakahashi H., Oishi Y., Chuang S-S., Morii S. Effects of tissue fixation and processing on proliferating cell nuclear antigen (PCNA) immunohistochemistry. Acta Pathol Jpn 42:621-623, 1992en_US
dc.identifier.citedreferenceHall PA, Levison DA, Woods AL, Yu Cc-W, Kellock DB, Watkins JA, Barnes DM, Gillet CE, Camplejohn R., Dover R., Waseem NH, Lane DP Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162:285-294, 1990en_US
dc.identifier.citedreferenceLeong As-Y, Milios J., Tang SK Is immunolocalization of proliferating cell nuclear antigen (PCNA) in paraffin sections a valid index of cell proliferation ? Appl Histochem 1:127-135, 1993en_US
dc.identifier.citedreferenceTheunissen PHMH, Leers MPG, Bollen ECM. Proliferating cell nuclear antigen (PCNA) expression in formalin-fixed tissue of non-small cell lung carcinoma. Histopathology 20:251-255, 1992en_US
dc.identifier.citedreferenceLeach FS, Tokino T., Meltzer P., Burrell M., Oliner JD, Smith S., Hill DE, Sidransky D., Kinzler KW, Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234, 1993en_US
dc.identifier.citedreferenceCordon-Cardo C., Latres E., Drobnjak M., Oliva MR, Pollack D., Woodruff JM, Marechal V., Chen J., Brennan MF, Levine AJ Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799, 1994en_US
dc.identifier.citedreferenceFlorenes VA, Maelandsmo GM, Forus A., Andreassen A., Myklebost O., Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status. J Natl Cancer Inst 86:1297-1302, 1994en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.